Navigation Links
Medivir Interim Report, 1 January - 30 September 2010
Date:10/22/2010

commercial value of our innovative cold sore product Xerclear(R)/Xerese(R ) and have signed two further agreements in different geographic markets.

The success demonstrated with Xerclear(R) and Xerese(R) shows Medivir's ability to develop and commercialize products and collaborate with blue-chip partners.

Following the successful rights issue concluded in June 2010 we are in healthy financial position and have therefore been able to remain focused on developing our exciting portfolio of early-phase projects for infectious diseases.

Medivir is positioned uniquely among specialty pharmaceutical companies with a potential blockbuster Hepatitis C therapy in late-stage development, a marketed product, Xerclear(R)/Xerese(R), approaching international launch, a broad earlier pipeline and a solid financial position. Medivir will now remain focused on creating further shareholder value and continues to gain momentum in its strategic goal to become a profitable specialty pharmaceutical company. We look forward to sharing our exciting future news flow going forward with both our patients and our shareholders as we continue to build the growth in this business."

For the full Q3 report please visit http://www.medivir.se. For more information, please contact Rein Piir, CFO and VP, Investor Relations, mobile: +46(0)70-853-7292. Ron Long, CEO, phone: +46(0)8-5468-3113. Forthcoming financial information and calendar Financial Statement will be published on 22 February 2011. Three-month Interim Report will be published on 5 May 2011. Annual General Meeting will be held on 5 May 2011.

Additional information on Medivir's operations is available on the company's website, http://www.medivir.se.


'/>"/>
SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® extracorporeal cytokine adsorber to purify ... of Dr. Joerg Scheier , M.D. as ... is a specialist in intensive care medicine and ... experience in treating critically-ill patients and in the ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced ... Notification Application (510k) with the US Food and Drug ... Medical expects feedback from the FDA during the next ... following FDA pre-market clearance. Additional pre-market regulatory filings are ... CEO for BRH Medical, commented, "We are thrilled to ...
(Date:4/27/2015)... 2015 BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues ("BioLife" or ... and Drug Administration has confirmed acceptance of the Company,s ... not an endorsement nor approval of BioLife,s products for ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 2CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 4CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 5BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2BioLife Solutions Submits FDA Master Files for Cell Thawing Media Products 2BioLife Solutions Submits FDA Master Files for Cell Thawing Media Products 3BioLife Solutions Submits FDA Master Files for Cell Thawing Media Products 4
... - 12-week study concludes that new cosmeceutical improves skin ... Calif., May 4 Senetek PLC (OTC ... the development of technologies that target the science of ... "Topical PRK-124 (0.125%) Lotion for Improving the Signs and ...
... Experience Significant Improvement in Ocular Surface Disease and Quality ... Inc. announced today that results from a large (n ... ophthalmic insert will be presented this week during the ... Vision and Ophthalmology (ARVO), May 3-7, Ft. Lauderdale, FL, ...
Cached Medicine Technology:Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 2ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 3ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 4ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 5
(Date:4/27/2015)... April 27, 2015 The Doctors on ... connect clients of personal injury attorneys with the best doctors ... has seen steady growth throughout their history and that trend ... DC and his team in the Tujunga / ... doctor and massage therapist, patients can find comprehensive care and ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Data Integrity ... Within Your Operations or Your Partners/Suppliers, **FDAnews Webinar**, May ... http://www.fdanews.com/DataIntegrity , Data integrity issues have become ... few years., Uncovering data integrity issues within manufacturing operations ... integrity issues come to light, remediating them can be ...
(Date:4/27/2015)... Como, Italy (PRWEB) April 27, 2015 ... that the design project SMRT IMAGE Lumica by Boombang ... of the Platinum A' Design Award in Scientific Instruments, ... Category. , Insights on SMRT IMAGE Lumica, Boombang Inc ... Product work SMRT IMAGE Lumica explained “SMRT Image Lumica ...
(Date:4/27/2015)... Telematics Berlin is Europe’s biggest Automotive ... CE players and the government to discuss the opportunities ... car. This year’s panel on connected car security with ... Commission, is an opportunity to hear and contribute towards ... Automotive Security Standard for years to come. , ...
(Date:4/27/2015)... Attorney Dan Newlin, of the Law ... his clients, took that commitment to a whole new level ... makes it easier for existing and potential clients to contact ... brand and added value to the firm’s services, #Dan covers ... Newlin has law offices. , “I knew the pound sign ...
Breaking Medicine News(10 mins):Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:Boombang Inc Design Team wins Platinum in A' Medical Product Design Awards 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:Dan Newlin Hashtags It With #Dan 2
... healthy crackle in the air! We have just been chipped in ... – chips! Wipe away that guilt// and let yourself have a ... complete range of McCain’s frozen chips has received the ‘green-signal’ from ... fat and saturated fat. The agency has accorded this brand of ...
... hundred villages in India will soon be well equipped ... centers - with the active involvement// of Indian American ... we would promote better hygiene, clean drinking water and ... also be given to creating awareness about vector borne ...
... with gonorrhea is probably twice as likely to develop bladder ... results in the British Journal of Cancer, lead author David ... the statement based on case studies of around 51,000 American ... men suffering from gonorrhea. Results analyzed showed that ...
... specially grown soy beans may prove to be successful ... says Tulane //University cancer researcher Matthew Burow. ... with ovarian and breast cancer tumors that are stimulated ... further growth of the tumors by interfering with the ...
... "gold-standard" amongst researchers for scientific studies. On the one ... has also questioned the worth of allopathic medicine practices, ... medicine (CAM) practices. Majority of CAM practices are difficult, ... ,The question arises as to whether EBM principles are ...
... blood thinning drugs quintupled during the 1990s, according to a ... than tenfold. ,Most of the increase is due ... prescribed to prevent blood clotting. Blood clots can lead to ... brain hemorrhage is a stroke caused by bleeding in the ...
Cached Medicine News:Health News:Better Healthcare for 100 Villages - Courtesy Indian American Physicians 2Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Open wire style blades allow complete manipulation of the phaco tip inside the eye. Lid control is excellent, exposure is maximized, and the likelihood of positive pressure is reduced....
Pediatric model. Blades: 10 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: